COMMUNIQUÉS West-GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH- [...]
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
26/02/2026
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% [...]
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
26/02/2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
26/02/2026
Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher [...]
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
26/02/2026
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]
ZSFab Announces First Clinical Use of 20° Hyperlordotic Cervical Cages in Puerto Rico
26/02/2026
WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dr. Fernando Villamil recently performed a three-level anterior cervical discectomy and fusion (ACDF) at Ashford Hospital in Puerto Rico using ZSFab’s 20° InterConnect™ [...]
MacroGenics to Participate in Upcoming Investor Conferences
26/02/2026
ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Ryoncil® Profits Underpinning Substantial Growth Pipeline
27/02/2026
Financial Results and Operational Update for Half-Year Ended December 31, 2025 NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for [...]
La Fondation canadienne du rein souligne la nécessité pour les Canadiens d'agir pour leur santé rénale
26/02/2026
Agissez pendant ce Mois de la santé rénale et à l'approche de la Journée mondiale du rein 2026 MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Alors que le Mois de la santé rénale débute, La Fondation canadienne du rein [...]
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
26/02/2026
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE [...]
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
26/02/2026
This press release is not intended for UK media HERNEXEOS ® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial 1 Accelerated approval [...]
HelpAlert Launches Elderly Welfare Check-In App in the United States That Requires No Wearable Device And Is Very Simple To Use.
26/02/2026
Voice-based system delivers automated daily welfare calls and smart escalation alerts using existing landline or mobile phones Los Angeles, CALIFORNIA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- HelpAlert , an elderly welfare [...]
GENFIT : Information financière du quatrième trimestre 2025 et point sur les activités de la Société
26/02/2026
Trésorerie et équivalents de trésorerie s’élevant à 101,1 millions d’euros au 31 décembre 2025 Revenus s’élevant à 65,4 millions d’euros pour l’exercice 2025 Solide performance d’Iqirvo® d’Ipsen dans la PBC (> USD [...]
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
26/02/2026
NANTES, France, February 26, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced that the Independent Data Monitoring Committee (IDMC) has issued a second positive [...]
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
26/02/2026
Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounted to €65.4 million as of December 31, 2025 Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in year one) [...]

Pages